Real-world evidence (RWE) solutions market predicted to be worth $3.13 billion by 2027
20 October 2021
- With a shift towards personalised healthcare and the rising emergence of rare diseases, healthcare and research organisations are facing challenges posed by high costs and lengthy timelines of delivering medicines to patients as the development of new pharmaceutical entities is time-consuming, extremely costly, and of high risk with little chance of successful outcome
- As the COVID-19 outbreak continues to take its toll on global markets, real-world evidence (RWE) is set to become the most influential emerging technology to help in the fight against the COVID-19 outbreak as it provides valuable insights to understand better, monitor, and prepare for the challenges caused by the pandemic
- Oncology accounted for the largest share in 2020 and is also expected to witness the fastest growth during the forecast period owing to the rising prevalence of cancer worldwide, growing R&D expenditure for cancer drugs, and increased adoption of RWE for innovation in oncology
Click here to learn more.
SVMPharma is an innovative strategic consultancy, specialising in Real-World Evidence (RWE) for the pharmaceutical industry. SVMPharma generates RWE within UK and Europe through bespoke online Real-World Treatment Evaluators, leading to successful health technology appraisal (HTA) submissions. Clinical trial programmes do not reflect real-world clinical practice and outcomes, RWE supplements and enhances clinical datasets. SVMPharma’s specialist teams focus on delivering the outcomes that matter to your brand.
For more information, please visit www.svmpharma.com and contact us at email@example.com